Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.

Transl Oncol · 2021 · PMC7723809 · PMID 33395752

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In conclusion, there was a trend toward improved survival with ibrutinib and nivolumab in patients with DLBCL with elevated PD-L1, although the differences did not reach statistical significance.

also in 111,027 other papers

showed a trendno p-value reported

Patients with DLBCL and PD-L1 elevation showed a trend toward improved response rates and prolonged survival with ibrutinib and nivolumab, with statistical significance reached for the association between PD-L1 expression and CR ( p = 0.028).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.